Quickly find freely available drug and population models in our PBPK model repository.
The models provided have been collated from published examples which authors have shared in our Published Model Collection or developed as part of various global health projects in our Global Health Collection. This search facility searches both model collections simultaneously.
To contribute published user compound and/or population files, upload your files here: Upload Model Files
Brand Name(s) include: Coartem (artemether, lumefantrine), Riamet (artemether, lumefantrine)
Disease: Malaria
Drug Class: Antimalarials
Related Files: Artemether – drug partner in fixed dose combinations
Date Updated: December 2022
Absorption Model |
|
Volume of Distribution Details |
Note: Kp scalar and Kp adipose used |
Route of Elimination |
CYP3A4 (40%); non-specific hepatic metabolism (60%) |
Perpetrator DDI |
|
Validation |
|
Limitations |
|
Updates in V19 |
|
Brand Name(s) include: Biltricide, Cysticide, Praquantel
Indication: Schistosomiasis and clonorchiasis/opisthorchiasis due to the liver flukes
Drug Class: Anthelmintic
Version: 22
Date Updated: February 2024
Absorption Model |
|
Volume of Distribution Details |
Full model (method 3) |
Route of Elimination |
|
Perpetrator DDI |
|
Validation |
|
Limitations |
|
Note: additional dissolution data 0.5 hr 55% not captured in the supplemental materials of the publication
An optimized Rosuvastatin (V19) model was used and DDIs predominantly driven by gut BCRP inhibition are reasonably recovered. Altogether, the following inhibitors were used: Capmatinib Fenebrutinib Fostamatinib Itraconazole Zepatier The workspace represents the DDI between Rosuvastatin and Fenebrutinib. Notes: - The fuGut in the inhibitor file is set as user input to 1. - An additional systemic clearance of 1.1 L/h is included in the submitted file. Link to the publication with further details: http://doi.org/10.1002/psp4.12672
11 |